EVENT IN GREECE
A program licensed by
the American Society of Clinical Oncology
2–3 OCTOBER, 2020
Hotel TITANIA
ATHENS

Organized by
E.P.E.I.K.
RESEARCH & TRAINING INSTITUTE
OF CLINICAL ONCOLOGY

Under the Auspices of
E.O.N.E
HELLENIC SOCIETY OF MEDICAL ONCOLOGY
Welcome Letter

Dear Colleagues,

Oncology is evolving rapidly, through the years and the integration of scientific progress in the daily practice is a challenge but also a necessity. Significant developments and steps forward have been made in recent years, in the field of diagnosis and treatment of oncologic patients.

Every year the ASCO Meeting is the biggest scientific event within the international oncologic community where the latest clinical and scientific breakthroughs are discussed while, new therapeutic agents are firstly presented. We are extremely proud to welcome all of you to the official “Best of ASCO 2020 Annual Meeting, Event in Greece”, that is held in Athens, at 2-3 October 2020.

This Educational Meeting aims to present the most interesting studies from the ASCO Annual Meeting, 2020 and highlight the concerns that may arise with the incorporation of these new data into our daily practice.

The Organizing and Educational Committee, in collaboration with ASCO, chose the studies that will be presented with the original slides, as they were presented during the recent Meeting and will be thoroughly discussed. The thematic round tables that have been created and the participated selected speakers, according to their experience and expertise will focus on and will point out the changes that these new data will bring to the daily practice of Oncology in our country.

Therefore, we welcome you to this Meeting with the hope and belief that our effort will be a substantial contribution to the Greek Oncology community especially, to those colleagues, who did not have the opportunity to attend the Annual ASCO Meeting, 2020.

Best regards

On behalf of the Organizing Committee

Athanasios Kotsakis

MD, PhD, Associate Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Director of the Department of Medical Oncology, University General Hospital of Larissa
Friday, October 2, 2020

12.00 Welcome and Chair Remarks

12.00-12.30 Session 1: General
Chairperson: E. Tselepatiotis, I. Giozos
Presenter: N. Tsoukalas

- **LBA110** Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).
- **12008** Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV).

12.20-12.30 General Discussion

12.30-13.25 Session 2: Breast Cancer (I)
Chairpersons: A. Ardavanis, D. Tryphonopoulos

- **506** MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.
- **500** Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
- **504** ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.

12.50-13.05 Presenter 2: E. Vasilii

- **LBA 2** A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
- **1007** PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.

13.05-13.25 Discussant: D. Tryphonopoulos

13.25-14.30 Session 3: Breast Cancer (II)
Chairpersons: V. Barbounis, F. Zagouri

13.25-13.40 Presenter 1: I. Kotsantis

- **1005** Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
THE FUTURE BEGINS.
13.40-14.00 Presenter 2: E. Moirogiorgou

**1002 TBCRC 048:** A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

**1000 KEYNOTE-355:** Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

14.00-14.20 Discussant: V. Barbounis

14.20-14.30 General Discussion

14.30-15.15 Lunch Break

15.15-16.10 Session 4: Malignant Melanoma

Chairpersons: H. Gogas, K. Kalbakis

15.15-15.30 Presenter 1: A. Laskarakis

**10000** Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.

**10001** Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.

**10065** Cemiplimab as first intervention for patients with locally advanced cutaneous squamous cell carcinoma.

15.30-15.40 Presenter 2: J. Duran-Moreno

**10004** Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

**10006** Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

**10005** Ipiilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

15.40-16.00 Discussant: D. Bafaloukos

16.00-16.10 General Discussion

16.10-17.30 Session 5: Genitourinary Cancer (Non-Prostate cancer)

Chairpersons: N. Androulakis, K. Koutsoukos

16.10-16.30 Presenter 1: A. Tsiara

**5000** IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

**5011** Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study. (abstract 5011)
Πριν τη συνταγογράφηση συμβουλευτείτε την ΠΧΠ που διατίθεται και στην ιστοσελίδα του EMA: www.europa.eu

REGENERON | SANOFI GENZYME

Sanofi-Aventis A.E.B.E.
Λεωφ. Συγγρού 348, Κέρκυρα, 176 74, Κολωνία
Τηλ.: 210 90 01 600, Fax: 210 92 49 088, www.sanofi.gr
Q2SFLL21.02.00015a 02/2020

▼ Το φάρμακο αυτό τελείως υπό αυτόνομη επιθεωρητική παρακολούθηση. Αυτό θα επηρεάζει το τρόπο προσδιορισμού τιμών πληροφοριών σαφής, ζητείται από τους επαγγελματίες ψηφία να αναφέρουν απόκεντρως σε ηλεκτρονικές επιστολές παθολογικές συνδρομές επικοινωνίες. Ελληνικός εκθέτος 4-B για την ηλεκτρική ασφαλιστική οικονομίας ενεργειών.
LBA1 Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

16.30-16.50 Presenter 2: T. Tegos

5008 Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). (abstract 5008).

5001 Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

5006 Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

16.50-17.10 Discussant: E. Lianos

17.20-17.30 General Discussion

17.30-17.45 Break

17.45-18.15 Session 6: Sarcomas
Chairpersons: I. Boukovinas, D. Tzaninis

17.45-18.05 Presenter 1: K. Tsapakidis

11500 Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).

11503 Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.

11504 Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.

11556 Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202. Roberta Sanfilippo et al.

18.05-18.15 General Discussion

18.15-19.20 Session 7: Gastrointestinal (Non-Colorectal) Cancer
Chairpersons: P. Papakostas, N. Ziras

18.15-18.35 Presenter 1: V. Papadopoulos

4500 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.

4502 Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.

4501 Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion - A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
18.35-18.50 Presenter 2: K. Stouraiti

**4504** SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfinirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

**4508** Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

18.50-19.10 Discussant: A. Karampeazis

19.10-19.20 General Discussion

19.20-20.40 **Session 8: Colorectal Cancer**
Chairpersons: A. Koumarianou, P. Kosmidis

19.20-19.40 Presenter 1: P. Katsaounis

**LBA4** Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study.

**3006** Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.

**4005** A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study.

19.40-20.10 Presenter 2: C. Avgerinou

**4004** Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

**4000** A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

**4001** Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

20.10-20.30 Discussant: T. Makatsoris – ZOOM CONNECTION

20.30-20.40 General Discussion
Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση
Προτείνουμε συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία
Saturday October 3, 2020

09.00-09.30 **Session 9: Central Nervous System Tumors**
Chairpersons: E. Razis, G. Rigakos

09.00-09.20 Presenter: N. Asimakopoulou

**2500 Randomized phase III study of high-dose methotrexate and whole brain**
radiotherapy with or without concomitant and adjuvant temozolomide in patients
with newly diagnosed primary central nervous system lymphoma: JCOG1114C.

**107 Updated entrectinib data in children and adolescents with recurrent or refractory**
solid tumors, including primary CNS tumors. (abstract 107).

**2504 Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts)**
with recurrent/progressive glioma: Updated results from the phase I non-enhancing
glioma population.

09.20-09.30 General discussion

09.30-10.05 **Session 10: Genetics**
Chairpersons: E. Saloustros, G. Samelis

09.30-09.55 Presenter: G. Lypas

**1501 Tumor/normal genomic profiling in patients with metastatic solid tumors identifies**
pathogenic germline variants of therapeutic importance.

**1508 Uptake of oophorectomy in women with findings on multigene panel testing:**
Results from the Prospective Registry of Multiplex Testing (PROMPT).

**1505 BARCODE 1:** A pilot study investigating the use of genetic profiling to identify
men in the general population with the highest risk of prostate cancer to invite for
targeted screening.(abstract 1505)

09.55-10.05 General Discussion

10.05-11.10 **Session 11: Non-Small Cell Lung Cancer (I)**
Chairpersons: A. Karampeazis, Ch. Panopoulos

10.05-10.30 Presenter 1: M. Drizou

**9005 CTONG1104:** Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC
with EGFR mutation - Final overall survival analysis of the randomized phase III
trial 1 analysis of the randomized phase III trial.

**LBA5** Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation
positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

**9506 NEJ026:** Final overall survival analysis of bevacizumab plus erlotinib treatment for
NSCLC patients harboring activating EGFR-mutations.
στην κατηγορία των CDK4/6 αναστολέων

η γραμμή θεραπείας και σε επόμενες

κάψουλα την ημέρα

μόνο συνιστώμενος έλεγχος παρακολούθησης

ΣΗΜΑΝΤΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ ΑΣΦΑΛΕΙΑΣ

To IBRANCE αντιενδοκινητικά σε περιπτώσεις υπερευθυδηθίας στο δραστικό ουσία ή σε κάποια από τα έδοκα, καθώς και σε ασθενείς οι οποίοι λαμβάνουν σκευάσματα που περιέχουν αντιβιοτικά/βαθμιαδορικά (St. John's Wort). Οι πιο συχνές αντιδράσεις ενέργειας (≥ 20%) απασχολούν Βαθμού 1 ή 2, αναλογικά σε ασθένες που ελάχιστο palbociclib σε τρανσλανσιονικές ελληνικές μελέτες ή σε αδυναμία, λαμβάνει, σεατομαϊκή, αναμία, δίνθρος, αιμοκτονία και θρομβομετάβαση. Οι πιο συχνές (≥ 20%) αντιδράσεις ενέργειας Βαθμού > 2 του palbociclib είναι αδυναμία, λαμβάνει, θλιψάμα, κόπωση, και αιμοκτονία //

CDK4/6 = Κυκλινο-αντιδραστήρες, κινάκιος 4/6, LHRH = ορμονική αποκλειστική της αρσενικότητας ομίλων


Η συντεταγμένη Περίληψη Χαρακτηριστικών του Προδόσιμου δημιουργείται σε άλλα σελίδα του παρόντος (σελ.1A).

Ολοκληρώθηκε να γίνουν τα φάρμακα πιο απαισπάλω και
Αναφέρετε
ΟΛΕΣ τις αντιδράσεις ενέργειας για
ΟΛA τα φάρμακα
Συμπληρώνεετε την «ΚΩΣΤΙΝΗ ΚΑΡΤΑ»

Pfizer Ελλάς Α.Ε. Λ. Μεσογείων 243, Ν. Χωρικά 15451, Αθήνα, Ελλάδα, Τηλ. Επικοινωνίας 210-9796803, Αριθ. Γ.Ε.ΜΗ. 000249901000
Pfizer Ελλάς Α.Ε. (CYPRUS BRANCH) Λεωφόρος Αθηνάς 28, 2018 Λευκωσία, Κύπρος, Τηλ. Επικοινωνίας +357 22 817890
10.30-10.50 Presenter 2: D. Ziogas

9504 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

9515 Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).

9508 First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS).

10.50-11.10 Discussant: A. Boutis

11.10-11.30 Coffee Break

11.30-12.15 Session 12: Non-Small Cell Lung Cancer-Immunotherapy (II)

Chairpersons: G. Koumakis, C. Kourousis

11.30-12.00 Presenter 1: I. Samaras


9501 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs chemo (4 cycles) as first-line (1L) treatment for stage IV or recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

9502 CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC). (abstract 9502).

9503 Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

12.00-12.15 Discussant: N. Pistamaltzian

12.15-13.10 Session 13: Small Cell Lung Cancer, Mesothelioma

Chairpersons: E. Samantas, A. Grivas

12.15-12.45 Presenter 1: M. Theochari

9003 PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) - A PrECOG LLC study.

9002 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.

9001 KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

9000 Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161 (abstract 9000).

12.45-13.00 Discussant: A. Nikolaidi

13.00-13.10 General Discussion
Το δάρμα αυτό τελέιως υπολογίζεται στην κατούλτη στην έννοια της "κατούλτη της έκδοσης". Η ποιότητα κατασκευές περιέχει υπολογιστή με τους υπολογιστές έως την έκδοση 4.0 των NGI O&T. "Λεμπρόβλεπτη" ή "φούξιατράπεζη" ή "Φούξιατράπεζη" ή "ζωοεκπληκτική" ή "ζωοεκπληκτική". Η στοιχειοθέτηση περιλαμβάνει τα εργασιακά-παραθυρόπνευμα που περιγράφηκαν σε συγκεντρωτικά δεδομένα 3 τυπωμένων μελέτων (N = 872).
13.10-14.00 Session 14: Head and Neck cancer
Chairpersons: A. Argyris, C. Kosmas

13.10-13.30 Presenter: P. Katsaounis

**6500** Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).

**6502** Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

**6503** Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.

13.30-13.50 Presenter: P. Gouveris

**6504** Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.

**6505 KEYNOTE-048:** Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

**6506** Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.

13.50-14.00 General Discussion

14.00-15.00 Light Lunch

15.00-16.15 Session 15: Genitourinary Cancer (Prostate cancer)
Chairpersons: M. Tsiatas, C. Kourousis

15.00-15.25 Presenter 1: A. Markou

**5515** Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

**5514** Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

**5516** Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

**5504** Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).

15.25-15.40 Discussant: F. Koinis

15.40-16.05 Presenter 2: A. Tzovaras

**5500** TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). (abstract 5500)
5502 Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.

5506 Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC). Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

5559 Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.

16.05-16.15 General Discussion: Z. Zafeiriou

16.15-17.15 Session 16: Gynecologic Cancer
Chairpersons: S. Xynogalos, T. Panoskaltsis

16.15-16.35 Presenter 1: A. Ntokou

6007 Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial. (abstract 6007)

6000 Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.

6006 Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.

16.35-16.55 Presenter 2: E. Res

6002 Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

6003 A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

6004 Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer (abstract 6004).

16.55-17.15 Discussant: I. Syrios

17.15-17.45 Break

17.45-20.10 Session 17: Molecular Biomarkers, Early clinical trials, Immunotherapy Biomarkers
Chairpersons: V. Georgoulias, A. Kotsakis

17.45-18.10 Presenter 1: I.F. Dimitrakopoulos

1502 Characterization of patients with multiple primary tumors (abstract 1502).

103 NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment. (abstract 103).

1009 Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials (abstract 1009).
Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy. (abstract 105)

18.10-18.20 General Discussion

18.20-18.45 Presenter 2: G. Goumas

2505 A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitididine. (abstract 2505)

3503 Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199). (abstract 3503)

3506 Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. (abstract 3506)

9505 Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). (abstract 9505)

18.45-18.55 General Discussion

18.55-19.15 Presenter 3: E. Kontopodis

11507 A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER). (abstract 11507)

3004 A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD 1 and LAG 3, in patients with unresectable or metastatic neoplasms. (abstract 3004)

3005 PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.

TPS5592 A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.

19.15-19.25 General Discussion

19.25-20.00 Presenter 4: D. Stefanou

6010 A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. (abstract 6010)

3007 Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types. (abstract 3007)

3008 Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. (abstract 3008)

5009 Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). (abstract 5009)

20.00-20.10 General Discussion

20.10 Closing Remarks
Faculty

N. Androulakis Head of the Medical Oncology Department, Venizeleio General Hospital of Heraklion, Heraklion, Crete

A. Ardavanis MD, PhD, Scientific Director of the 1st Oncology Unit, Saint Savvas Anticancer Hospital, Athens

A. Argyris MD, PhD, FACP, Medical Oncologist, Director, 1st Department of Medical Oncology, Hygeia Hospital, Athens, Greece, Professor, Medical Oncology, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA, Adjunct Professor, University of Texas Health Science Center at San Antonio, Texas, USA

N. Asimakopoulou Resident of Medical Oncology, Evangelismos Hospital, PhDc in Oncology, School of Medicine, University of Crete, Crete

C. Avgerinou Medical Oncologist, 2nd Medical Oncology Department, Metropolitan General, Athens

D. Bafaloukos MD, PhD, Medical Oncologist, Emeritus Professor of University of WA., Director of 1st Oncology Department, Metropolitan Hospital, Athens

V. Barbounis MD, PhD, Medical Oncologist, Director of the 3rd Oncology Clinic, Metropolitan Hospital, Athens

I. Boukovinas MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit Bioclinic Thessaloniki

A. Boutis MD, Medical Oncologist, Theageneion Cancer Hospital, Thessaloniki

F.I. Dimitrakopoulos MD, PhD, Medical Oncologist, Division of Oncology & Molecular Oncology Laboratory, Department of Medicine, University of Patras

M. Drizou Medical Oncologist, 2nd Oncology Department, Metropolitan Hospital, Athens

J. Duran - Moreno Medical Oncologist, Athens

V. Georgoulias Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Heraklion, Crete

I. Giozos MD, PhD, FCCP, Pulmonologist, Oncology Unit, Sotiria Hospital, National & Kapodistrian University of Athens, Membership Committee, International Association for the Study of Lung Cancer, Athens

H. Gogas Professor in Medical Oncology, Head 1st Department of Medicine, National and Kapodistrian University of Athens, Athens

G. Goumas Medical Oncologist, MSc Locum Consultant, 2nd Department of Oncology Saint Savvas Anticancer Hospital, Athens

P. Gouveris MD, PhD, Medical Oncologist, Consultant, 2nd Department of Medical Oncology, Saint Savvas, Anticancer Hospital, Athens

A. Grivas Medical Oncologist, Consultant, 2nd Department of Medical Oncology, Saint Savvas Anticancer Hospital of Athens, Athens

K. Kalbakis Director, Medical Oncology Clinic, University Hospital of Heraklion, Heraklion, Crete
T. Panoskaltsis MD, PhD, FRCOG, Assistant Professor in Obstetrics & Gynaecology, National & Kapodistrian University of Athens, Medical School, Athens

V. Papadopoulos Medical Oncologist, University Hospital of Larissa, Larissa

P. Papakostas Head of 2nd Oncology Department, Metropolitan General Hospital, Athens

N. Pistamaltzian MD, PhD, Medical Oncologist, Oncology Department, Mitera Hospital, Athens

E. Razis MD, PhD, Medical Oncologist, Director, 3rd Oncology Department Hygeia Hospital, Director, Contemporary Oncology Team, Athens

E. Res MD, PhD, Medical Oncologist, General Oncological Hospital of Kifissia, Agioi Anargyroi, Athens

G. Rigakos MD, MSc, Medical Oncologist, Consultant, 3rd Oncology Department, Hygeia Hospital, Athens

E. Saloustros Assistant Professor of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa

E. Samantas MD, Consultant Medical Oncologist, 2nd Oncology Department, Metropolitan Hospital, Athens

I. Samaras MD, Medical Oncologist, University Hospital of Larissa, Larissa

G. Samelis MD, PhD, Scientific Director of the Oncology Unit, Hippocrates General Hospital of Athens, President of the Hellenic and International Society of the Molecular-Targeted Treatments, Athens

D. Stefanou Medical Oncologist, Oncology Unit, 3rd Department of Medicine, Sotiria General Chest Disease Hospital, Athens

K. Stouraiti Consultant Medical Oncologist, Euroclinic Oncology Clinic of Athens, Athens

I. Syrios MD, MSc, PhD, Medical Oncologist, Hygeia Hospital, Athens

T. Tegos MD, PhD, Medical Oncologist, Evaggelismos General Hospital, Athens

M. Theochari Consultant, Laiko Hospital, Athens

D. Tryphonopoulos MD, PhD, MSc, Medical Oncologist, Saint Savvas Anticancer Hospital, Athens

K. Tsapakidis Medical Oncologist, University Hospital of Larissa, Larissa

E. Tselepatiotis Consultant Medical Oncologist, Hellenic NHS, Agioi Anargyroi Cancer Hospital, Athens

A. Tsiara Medical Oncologist, 5th Clinic of Medical Oncology, Hygeia Hospital, Athens

M. Tsiatas MD, PhD, BSc (Biol), Director Medical Oncologist, Department of Oncology and Cancer Clinical Trials Unit, Athens Medical Center, Athens

N. Tsoukalas MD, MSc, PhD, Medical Oncologist, MSc Bioinformatics, Deputy Director, Oncology Department, 401 General Military Hospital, Consultant, Henry Dunant Hospital Center, Athens

D. Tzanninis MD, Medical Director, Department of Oncology, Athens Medical Center, Athens

A. Tzovaras PhD, Medical Oncologist, Agios Savvas Anticancer hospital of Athens, Athens
E. Vasili Consultant, Medical Oncologist, 2\textsuperscript{nd} Oncology Department, Metropolitan Hospital Athens

S. Xynogalos MD, PhD, Department of Medical Oncology, Metaxa Memorial Cancer Centre, Piraeus

Z. Zafeiriou MD, MSc, Medical Oncologist, Theageneio Anticancer Hospital, Thessaloniki

F. Zagouri MD, PhD, Medical Oncologist, Associate Professor of National and Kapodistrian University of Athens, Athens

D. Ziogas MD, PhD, Academic Scholar in Medical Oncology, 1\textsuperscript{st} Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens

N. Ziras MD, PhD, Director, Medical Oncology Department, Metaxa Cancer Hospital of Piraeus
Info
Organized by

Under the Auspices of

Date
2-3 October, 2020

Venue
Hotel TITANIA
52, Panepistimiou Ave., Athens 10678 - Greece
Tel.: +30.210-33.26.000 Fax: +30.210-33.00.700
e-mail: titania@titania.gr

Official Language
The official language of the Meeting is English.

There will be a live streaming connection through a special platform.
You can watch the Conference online through the Link [www.nowcongress.gr](http://www.nowcongress.gr) and ask written questions throughout the presentations.

Certificate of Attendance
The certificate of attendance will be given to the participants at the end of the event.
Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program. The number of credits of Continuing Medical Education (CME-CPD) to be administered to the participants will be calculated on the basis of monitoring time.

The event will be awarded
By Hellenic Medical Association (Ph. M.A.) with 15 CME - CPD credits.

Best of ASCO and any related logos are trademarks of the American Society of Clinical Oncology.

Secretariat
Congress & Event Planning
2-4, Kastriotou Str., Athens - Greece  P.C.11476  T +30 210 7294559  E info@eventema.gr
Sponsors

With the Kind Support of

Astellas

AstraZeneca

Bristol Myers Squibb

Genesis

Ipsen

Lilly

MSD

Novartis

Pfizer Oncology

Pierre Fabre

Sandoz

Sanofi Genzyme

Event in Greece
για τις γυναίκες με HR+/HER2- μεταστατικό καρκίνο μαστού\textsuperscript{1,3}


\textbf{HR+/HER2-}: Βετοκά της ομοιολογικής υποδοχής και αρνητικός στον υποδοχέα 2 του ανθρώπινου επιδερμικού αυθεντικού παράγοντα

Πριν τη συνταγογράφηση συμβουλεύετε την Περίληψη Χαρακτηριστικών του Προϊόντος, που διατίθεται ΕΔΩ.

\textbf{NOVARTIS}

\textbf{Novartis (Ελλάς) A.E.B.E.}
12-χώροι, Εθνικής Οδού Αθηνών - Λευκάδα
144 51 Μεταμόρφωση
Τηλ.: +30 210 261 1712

Γραφεία Θεσσαλονίκης:
12-χώροι Εθνικής Οδού Βεσσαλονίκης - Ν. Μουσώνιον, 570 01 Θεσσαλονίκη
Τηλ.: +30 2310 424 039

\textbf{ΦΑΡΜΑΚΟΕΠΑΓΓΕΛΜΑΤΙΚΗ:} +30 210 2828812

\textbf{KISQALI®}
ribociclib 200mg tablets